NHP Acute Myocardial Infarction (AMI) Model
Acute Myocardial Infarction (AMI) remains one of the leading causes of morbidity and mortality worldwide. Despite significant advances in reperfusion therapies and interventional cardiology, many investigational therapies targeting myocardial protection, infarct remodeling, angiogenesis, and cardiac regeneration continue to face substantial translational challenges during clinical development.
Non-human primate (NHP) models offer unique advantages for cardiovascular research due to their close anatomical and physiological similarity to humans. Coronary artery anatomy, myocardial structure, electrophysiology, and hemodynamic characteristics in NHPs closely resemble those observed in patients, providing a highly relevant platform for evaluating novel cardiovascular therapeutics.
At Prisys Biotechnologies, we have established a minimally invasive NHP AMI model using catheter-based coronary intervention under Digital Subtraction Angiography (DSA) guidance, enabling clinically relevant assessment of myocardial injury, cardiac function, and therapeutic efficacy.
Model Establishment
The model is induced through image-guided coronary intervention performed in a clinical-grade DSA operating suite.
Using percutaneous catheterization techniques, the target coronary artery-typically the left anterior descending artery (LAD)-is selectively accessed under real-time angiographic guidance. Controlled vascular occlusion induces regional myocardial ischemia and infarction, closely reproducing the pathophysiological process observed in human AMI.
Compared with traditional thoracotomy-based ligation approaches, this minimally invasive procedure reduces surgical trauma and systemic inflammatory interference while improving model consistency and survival rates.
Translational Advantages of the NHP AMI Model
Human-Relevant Cardiovascular Anatomy
NHP coronary artery distribution, myocardial architecture, and ventricular remodeling patterns closely resemble those of humans, supporting clinically relevant evaluation of ischemic injury and post-infarction remodeling.
Clinical Interventional Procedures
The model utilizes standard catheter-based cardiovascular intervention techniques commonly employed in clinical practice, facilitating translational assessment of both therapeutic agents and interventional devices.
Longitudinal Functional Assessment
The larger body size of NHPs allows repeated evaluation using clinical imaging systems and cardiac monitoring technologies throughout disease progression and treatment.
Clinical-Equivalent Endpoints
Researchers can assess cardiac structure and function using the same imaging modalities routinely applied in human cardiovascular studies, improving translational predictability.
Imaging and Functional Evaluation
Prisys integrates its Clinical Imaging Platform to provide comprehensive evaluation of myocardial injury and cardiac remodeling.
Echocardiography
Cardiac ultrasound is used to assess:
- Left ventricular ejection fraction (LVEF)
- Regional wall motion abnormalities
- Ventricular dimensions
- Cardiac remodeling progression
PET-CT Myocardial Imaging
PET-CT enables quantitative assessment of:
- Myocardial perfusion defects
- Infarct size
- Ischemic but viable myocardium
- Metabolic activity within injured cardiac tissue
These imaging endpoints provide objective measurements for evaluating cardioprotective and regenerative therapies.
Electrocardiography (ECG)
Typical AMI-related electrophysiological changes can be monitored longitudinally, including:
- ST-segment elevation
- Pathological Q-wave formation
- Chronic remodeling-associated ECG alterations
Applications in Drug Development
The NHP AMI platform supports preclinical evaluation across a broad range of cardiovascular therapeutic strategies, including:
- Cardioprotective agents
- Anti-remodeling therapies
- Anti-fibrotic compounds
- Angiogenic therapies
- Biologics and monoclonal antibodies
- Cell and gene therapies
- Catheter-delivered therapeutics
- Drug-device combination products
The model can also support Pharmacodynamics (PD) assessment, biomarker validation, and translational imaging endpoint development for IND-enabling studies.
Why Choose Prisys Biotechnologies?
Prisys Biotechnologies combines extensive NHP cardiovascular research experience with advanced clinical imaging and interventional capabilities, including:
- AAALAC-accredited NHP research facility
- Clinical-grade DSA interventional suite
- MRI, CT, PET-CT, and ultrasound imaging platforms
- Experienced cardiovascular intervention and imaging teams
- Longitudinal disease monitoring capabilities
- Integrated PK/PD and biomarker evaluation services
By combining clinically relevant disease induction with multimodal imaging assessment, the Prisys NHP AMI model provides a valuable translational platform for cardiovascular drug development and therapeutic evaluation.
FAQ
Q: Why use an NHP model instead of rodent myocardial infarction models?
A: NHPs possess coronary anatomy, cardiac physiology, and ventricular remodeling characteristics that are substantially closer to humans than those of rodents, improving the translational relevance of efficacy and safety findings.
Q: How is myocardial infarction induced in the Prisys AMI model?
A: AMI is established through catheter-based coronary intervention under DSA guidance, typically involving controlled occlusion of the left anterior descending artery (LAD) to produce localized myocardial ischemia and infarction.
Q: Can cardiac function be monitored longitudinally?
A: Yes. The model supports repeated assessment using echocardiography, ECG, PET-CT, CT, and other clinical imaging modalities throughout the study period.
Q: What types of therapeutics can be evaluated?
A: The model is suitable for small molecules, biologics, monoclonal antibodies, regenerative therapies, cell and gene therapies, and catheter-based cardiovascular interventions.
Q: Does Prisys support image-guided coronary drug delivery studies?
A: Yes. Using its interventional cardiovascular platform, Prisys can support catheter-directed coronary administration approaches and subsequent evaluation of local pharmacodynamic and imaging endpoints.
Hot Tags: NHP Acute Myocardial Infarction (AMI) Model, research, study, monkey, gene therapy, Hemophilia A Nonhuman Primates, Myopia Hyperopia Nonhuman Primates Disease Model, NHP Lung Fibrosis, Middle Cerebral Artery Occlusion MCAO NHP Model Of Stoke Brain Ischemia, veterinary PK pharmacology, Acute Myocardial Infarction Nonhuman Primates Disease Model
You Might Also Like
Send Inquiry